Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $49.4286.
A number of research firms have recently issued reports on ASTH. Wall Street Zen lowered shares of Astrana Health from a “buy” rating to a “hold” rating in a report on Sunday. BTIG Research lifted their price objective on shares of Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. TD Cowen boosted their target price on shares of Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings upgraded Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. Finally, Needham & Company LLC raised their target price on Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a research report on Friday, May 8th.
Institutional Investors Weigh In On Astrana Health
Astrana Health Price Performance
NASDAQ ASTH opened at $39.16 on Wednesday. The stock’s 50-day moving average price is $41.39 and its two-hundred day moving average price is $33.12. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 1.05. The company has a market cap of $2.18 billion, a PE ratio of 47.76 and a beta of 0.87. Astrana Health has a 1 year low of $18.08 and a 1 year high of $51.60.
Astrana Health (NASDAQ:ASTH – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.46. Astrana Health had a net margin of 1.05% and a return on equity of 10.30%. The company had revenue of $972.52 million during the quarter, compared to analyst estimates of $985.62 million. During the same period in the prior year, the firm earned $0.19 earnings per share. The business’s quarterly revenue was up 48.5% on a year-over-year basis. On average, analysts predict that Astrana Health will post 1.31 EPS for the current year.
Astrana Health Company Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Read More
- Five stocks we like better than Astrana Health
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
